5. (Amended Twice) The method of Claim 1 comprising administering said retinoid composition by intravenous infusion.

B1

6. (Amended Twice) The method of Claim 1 wherein the composition comprising at least one interferon and a retinoid is administered at a frequency from daily to about 3 out of 7 days per week.

9. (Amended Once) A therapeutic treatment kit for the treatment of cancer comprising interferon, all-trans retinoic acid and instructional materials for the combined use of said all-trans retinoic acid and interferon.

B2

Please add the following new claims:

32. (New) The method of claim 16, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

33. (New) The method of claim 21, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

B3

34. (New) The method of claim 25, wherein alpha interferon is administered in an amount of about 3 to about 5 million IU.

REMARKS

Claims 1-31 are pending in the subject application. Claims 4-6, and 9 and have been amended. New claims 32-34 are presented herein. Applicant notes that claims 1-3, 7, 8, 10, 11, and 14-31 have been allowed. Accordingly, the allowed claims, claims 4-6 and 9, as amended, and new claims 32-34 are under consideration.

Claims 4-6 and 9 have been amended to clarify the claimed subject matter. Support for these amendments is found in the original claims and throughout the specification. Specifically,